[go: up one dir, main page]

RU2018144315A - КОНЪЮГАТЫ АНТИТЕЛА К cMet И ЛЕКАРСТВЕННОГО СРЕДСТВА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ - Google Patents

КОНЪЮГАТЫ АНТИТЕЛА К cMet И ЛЕКАРСТВЕННОГО СРЕДСТВА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ Download PDF

Info

Publication number
RU2018144315A
RU2018144315A RU2018144315A RU2018144315A RU2018144315A RU 2018144315 A RU2018144315 A RU 2018144315A RU 2018144315 A RU2018144315 A RU 2018144315A RU 2018144315 A RU2018144315 A RU 2018144315A RU 2018144315 A RU2018144315 A RU 2018144315A
Authority
RU
Russia
Prior art keywords
seq
amino acid
acid sequence
cdr
cmet
Prior art date
Application number
RU2018144315A
Other languages
English (en)
Other versions
RU2018144315A3 (ru
RU2740996C2 (ru
Inventor
Эдвард Б. РАЙЛИ
Луи НАУМОВСКИ
Кристиан Б. АЛЛАН
Цзеи ВАН
Марк Г. АНДЕРСОН
Дэниел Е. АФАР
Original Assignee
Эббви Байотерапьютикс Инк.
Эббви Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эббви Байотерапьютикс Инк., Эббви Инк. filed Critical Эббви Байотерапьютикс Инк.
Publication of RU2018144315A publication Critical patent/RU2018144315A/ru
Publication of RU2018144315A3 publication Critical patent/RU2018144315A3/ru
Application granted granted Critical
Publication of RU2740996C2 publication Critical patent/RU2740996C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Claims (62)

1. Конъюгат антитела к cMet и лекарственного средства ("ADC"), содержащий антимитотическое средство, связанное с антителом к cMet посредством линкера, где ADC характеризуется структурой формулы (I):
(I) [D-L-XY-]n-Ab,
или соответствующей ей соли, где
D представляет собой антимитотическое средство;
L представляет собой линкер;
Ab представляет собой антитело к cMet;
XY представляет собой ковалентную связь, связывающую линкер L с антителом Ab; и
n представляет собой целое число в диапазоне от 2 до 8;
где
L предусматривает валин-цитруллиновый (vc) линкер и характеризуется структурой формулы (IVb.2):
Figure 00000001
D представляет собой монометилауристатин E ("MMAE"), и ADC структурной формулы (I) характеризуется следующей структурой:
Figure 00000002
; и
Ab предусматривает антитело к cMet, которое содержит (i) VH-цепь, содержащую три CDR; и (ii) VL-цепь, содержащую три CDR, где
CDR №1 VH имеет аминокислотную последовательность: GYIFTAYTMH (SEQ ID NO: 112), CDR №2 VH имеет аминокислотную последовательность: WIKPNNGLANYAQKFQG (SEQ ID NO: 113), CDR №3 VH имеет аминокислотную последовательность: SEITTEFDY (SEQ ID NO: 114), CDR №1 VL имеет аминокислотную последовательность: KSSESVDSYANSFLH (SEQ ID NO: 115), CDR №2 VL имеет аминокислотную последовательность: RASTRES (SEQ ID NO: 116), и CDR №3 VL имеет аминокислотную последовательность: QQSKEDPLT (SEQ ID NO: 117),
и (iii) модифицированную шарнирную область, имеющую аминокислотную последовательность PKSCDCHCPPCP (SEQ ID NO: 170).
2. ADC по п. 1, где антитело к cMet содержит VH-цепь с SEQ ID NO: 78 и VL-цепь с SEQ ID NO: 79 или 81.
3. ADC по п. 1, где антитело к cMet содержит тяжелую цепь с SEQ ID NO: 86 или 88 и легкую цепь с SEQ ID NO: 87.
4. Фармацевтическая композиция, содержащая ADC по п. 3 и фармацевтически приемлемый носитель.
5. Фармацевтическая композиция по п. 4, характеризующаяся соотношением лекарственного средства и антитела ("DAR"), составляющим приблизительно 3,1.
6. Конъюгат антитела к cMet и лекарственного средства ("ADC"), содержащий сшивающее ДНК средство, связанное с антителом к cMet посредством линкера, где ADC характеризуется структурой формулы (I):
(I) [D-L-XY-]n-Ab,
или соответствующей ей соли, где
D представляет собой сшивающее ДНК средство;
L представляет собой линкер;
Ab представляет собой антитело к cMet;
XY представляет собой ковалентную связь, связывающую линкер L с антителом Ab; и
n представляет собой целое число в диапазоне от 2 до 8;
где
L предусматривает валин-аланиновый (va) линкер и характеризуется структурой формулы (IVd.3):
Figure 00000003
D представляет собой димер пирролобензодиазепина ("PBD"), и ADC структурной формулы (I) характеризуется следующей структурой:
Figure 00000004
Ab предусматривает антитело к cMet, которое содержит (i) VH-цепь, содержащую три CDR; и (ii) VL-цепь, содержащую три CDR, где
CDR №1 VH имеет аминокислотную последовательность: GYIFTAYTMH (SEQ ID NO: 173), CDR №2 VH имеет аминокислотную последовательность: WIKPNNGLANYAQKFQG (SEQ ID NO: 174), CDR №3 VH имеет аминокислотную последовательность: SEITTEFDY (SEQ ID NO: 175), CDR №1 VL имеет аминокислотную последовательность: KSSESVDSYANSFLH (SEQ ID NO: 176), CDR №2 VL имеет аминокислотную последовательность: RASTRES (SEQ ID NO: 177), и CDR №3 VL имеет аминокислотную последовательность: QQSKEDPLT (SEQ ID NO: 178),
и (iii) модифицированную шарнирную область, имеющую аминокислотную последовательность PKSCDCHCPPCP (SEQ ID NO: 170).
7. ADC по п. 6, где антитело к cMet содержит VH-цепь с SEQ ID NO: 78 и VL-цепь с SEQ ID NO: 79 или 81.
8. ADC по п. 6, где антитело к cMet содержит тяжелую цепь с SEQ ID NO: 171 и легкую цепь с SEQ ID NO: 172.
9. Способ лечения рака, представляющего собой солидную опухоль, при котором сверхэкспрессируется cMet, предусматривающий введение субъекту-человеку, у которого имеется указанный рак, фармацевтической композиции, содержащей конъюгат антитела к cMet и лекарственного средства ("ADC") и фармацевтически приемлемый носитель, где фармацевтическую композицию вводят в количестве и в течение периода времени, достаточных для обеспечения терапевтического эффекта, и где ADC характеризуется структурой формулы (I):
(I) [D-L-XY-]n-Ab,
или соответствующей ей соли, где
D представляет собой антимитотическое средство;
L представляет собой линкер;
Ab представляет собой антитело к cMet;
XY представляет собой ковалентную связь, связывающую линкер L с антителом Ab; и
n представляет собой целое число в диапазоне от 2 до 8;
где
L предусматривает валин-цитруллиновый (vc) линкер и характеризуется структурой формулы (IVb.2):
Figure 00000005
D представляет собой монометилауристатин E ("MMAE"), и ADC структурной формулы (I) характеризуется следующей структурой:
Figure 00000002
; и
Ab предусматривает антитело к cMet, которое содержит (i) VH-цепь, содержащую три CDR; и (ii) VL-цепь, содержащую три CDR, где
CDR №1 VH имеет аминокислотную последовательность: GYIFTAYTMH (SEQ ID NO: 112), CDR №2 VH имеет аминокислотную последовательность: WIKPNNGLANYAQKFQG (SEQ ID NO: 113), CDR №3 VH имеет аминокислотную последовательность: SEITTEFDY (SEQ ID NO: 114), CDR №1 VL имеет аминокислотную последовательность: KSSESVDSYANSFLH (SEQ ID NO: 115), CDR №2 VL имеет аминокислотную последовательность: RASTRES (SEQ ID NO: 116), и CDR №3 VL имеет аминокислотную последовательность: QQSKEDPLT (SEQ ID NO: 117),
и (iii) модифицированную шарнирную область, имеющую аминокислотную последовательность PKSCDCHCPPCP (SEQ ID NO: 170).
10. Способ по п. 9, где антитело к cMet содержит VH-цепь с SEQ ID NO: 78 и VL-цепь с SEQ ID NO: 79 или 81.
11. Способ по п. 9, где антитело к cMet содержит тяжелую цепь с SEQ ID NO: 86 или 88 и легкую цепь с SEQ ID NO: 87.
12. Способ по п. 9, где рак, характеризующийся сверхэкспрессией cMet, представляет собой немелкоклеточный рак легкого ("NSCLC").
13. Способ по п. 12, где NSCLC представляет собой плоскоклеточный NSCLC или аденокарциному.
14. Способ по п. 13, где плоскоклеточный NSCLC характеризуется IHC-показателем, составляющим от 2+ до 3+, у биоптата.
15. Способ по п. 13, где биоптат ткани опухоли, представляющей собой аденокарциному, характеризуется IHC-показателем, составляющим 3+, и/или H-показателем, превышающим 225.
16. Способ по п. 9, где ADC, нацеливающийся на cMet, вводят в дополнение к дополнительному противораковому средству.
17. Способ по п. 16, где дополнительное противораковое средство представляет собой ингибитор рецептора эпидермального фактора роста ("EGFR").
18. Способ по п. 17, где дополнительное противораковое средство представляет собой эрлотиниб.
RU2018144315A 2016-05-17 2017-05-17 КОНЪЮГАТЫ АНТИТЕЛА К cMet И ЛЕКАРСТВЕННОГО СРЕДСТВА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ RU2740996C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662337796P 2016-05-17 2016-05-17
US62/337,796 2016-05-17
PCT/US2017/033176 WO2017201204A1 (en) 2016-05-17 2017-05-17 ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE

Publications (3)

Publication Number Publication Date
RU2018144315A true RU2018144315A (ru) 2020-06-17
RU2018144315A3 RU2018144315A3 (ru) 2020-07-22
RU2740996C2 RU2740996C2 (ru) 2021-01-22

Family

ID=59014737

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018144315A RU2740996C2 (ru) 2016-05-17 2017-05-17 КОНЪЮГАТЫ АНТИТЕЛА К cMet И ЛЕКАРСТВЕННОГО СРЕДСТВА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Country Status (26)

Country Link
US (5) US20170348429A1 (ru)
EP (4) EP4233909A3 (ru)
JP (4) JP2019521087A (ru)
KR (3) KR102512597B1 (ru)
CN (3) CN114246953B (ru)
AU (1) AU2017268342B2 (ru)
BR (1) BR112018073574A2 (ru)
CA (1) CA3024386C (ru)
CY (2) CY1123256T1 (ru)
DK (2) DK3458102T3 (ru)
ES (2) ES2864150T3 (ru)
HR (2) HRP20201186T1 (ru)
HU (2) HUE053332T2 (ru)
IL (3) IL262869B (ru)
LT (2) LT3626273T (ru)
MX (1) MX2018014175A (ru)
NZ (1) NZ748314A (ru)
PL (2) PL3626273T3 (ru)
PT (2) PT3458102T (ru)
RS (2) RS60663B1 (ru)
RU (1) RU2740996C2 (ru)
SG (2) SG11201810034XA (ru)
SI (2) SI3626273T1 (ru)
SM (2) SMT202000467T1 (ru)
WO (1) WO2017201204A1 (ru)
ZA (1) ZA201808386B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3626273T (lt) 2016-05-17 2021-03-10 Abbvie Biotherapeutics Inc. Anti-cmet antikūnų vaisto konjugatai ir jų naudojimo būdai
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
ES2875365T3 (es) * 2016-11-23 2021-11-10 Lilly Co Eli Conjugados de fármaco de anticuerpos MET
CN110144325A (zh) * 2018-02-12 2019-08-20 深圳宾德生物技术有限公司 一种靶向性t淋巴细胞及其制备方法和应用
US20210260210A1 (en) 2018-03-13 2021-08-26 Zymeworks Inc. Anti-her2 biparatopic antibody-drug conjugates and methods of use
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
EP3774923A4 (en) 2018-03-28 2021-12-29 Mitsubishi Tanabe Pharma Corporation Drug conjugates of cmet monoclonal binding agents, and uses thereof
EP3854816A4 (en) * 2018-09-30 2022-09-07 Jiangsu Hengrui Medicine Co., Ltd. ANTI-B7H3 ANTIBODY EXATECAN ANALOGUE CONJUGATE AND ITS MEDICAL USE
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
MX2022001286A (es) * 2019-07-30 2022-07-19 Mythic Therapeutics Inc Construcciones de proteínas de unión a antígenos y usos de estas.
MX2022002886A (es) 2019-09-16 2022-04-06 Regeneron Pharma Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet.
CN112604004B (zh) * 2019-09-19 2022-05-10 中国医学科学院医药生物技术研究所 一类抗人egfr抗体药物偶联物及其制备方法与应用
CN110893236A (zh) * 2019-10-09 2020-03-20 中山大学 溶酶体靶向的抗体药物偶联物及其应用
US12103960B2 (en) 2020-05-08 2024-10-01 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
US20240165253A1 (en) * 2020-09-01 2024-05-23 Remegen Co., Ltd. Anti-c-met antibody-drug conjugate and applications thereof
WO2022078279A1 (zh) * 2020-10-12 2022-04-21 昆山新蕴达生物科技有限公司 抗体-药物偶联物及其应用
CN114533891B (zh) * 2020-11-24 2023-04-18 深圳先进技术研究院 一种靶向无痕释放药物缀合物及其制备方法与应用
CA3209786A1 (en) * 2021-02-03 2022-08-11 Mythic Therapeutics, Inc. Anti-met antibodies and uses thereof
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
JP2024514506A (ja) * 2021-04-06 2024-04-02 アッヴィ・バイオセラピューティクス・インコーポレイテッド テリソツズマブベドチンを使用した非小細胞肺がんの治療方法
IL306129A (en) 2021-04-07 2023-11-01 Mythic Therapeutics Inc Structures of antigen-binding proteins and antibodies and their uses
US20240376214A1 (en) 2021-04-08 2024-11-14 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates
UY39743A (es) * 2021-04-29 2022-11-30 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
WO2023086833A1 (en) 2021-11-09 2023-05-19 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
CN114369162B (zh) * 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
US20230285394A1 (en) 2022-03-11 2023-09-14 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzummab vedotin and osimertinib
AU2023350792A1 (en) * 2022-09-28 2025-03-27 Zymeworks Bc Inc. Antibody drug conjugates targeting c-met and methods of use
AU2023361155A1 (en) 2022-10-12 2025-04-03 Mythic Therapeutics, Inc. Lrrc-15-binding protein constructs and uses thereof
WO2024129585A1 (en) 2022-12-11 2024-06-20 Mythic Therapeutics, Inc. ANTI-cMET ANTIBODY DRUG CONJUGATES AND THERAPEUTIC USES THEREOF
FI20235292A1 (en) * 2023-03-13 2024-09-14 Glykos Finland Oy ANTIBODY SEXATECANE CONJUGATE
TW202500584A (zh) 2023-05-19 2025-01-01 法商施維雅藥廠 抗met抗體、抗體-藥物結合物、組合物及其用途
WO2025021151A1 (zh) * 2023-07-25 2025-01-30 江苏恒瑞医药股份有限公司 靶向c-Met的抗体-药物偶联物及其医药用途
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
WO2025078841A2 (en) 2023-10-11 2025-04-17 Antikor Biopharma Limited Antibodies, conjugates, and uses thereof
KR20250057672A (ko) * 2023-10-19 2025-04-29 (주)셀트리온 캄프토테신 유도체를 포함하는 항-c-MET 항체-약물 접합체
WO2025126157A1 (en) 2023-12-15 2025-06-19 Advesya Anti-il-1rap binding domains and antibody-drug conjugates thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0428534B1 (en) 1988-06-14 1995-03-29 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
AU5702298A (en) 1996-12-03 1998-06-29 Abgenix, Inc. Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
DK0970126T3 (da) 1997-04-14 2001-08-13 Micromet Ag Hidtil ukendt fremgangsmåde til fremstillingen af anti-humant antigen-receptorer og anvendelser deraf
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2301254T3 (es) 1998-11-18 2008-06-16 Genentech, Inc. Variantes de anticuerpos con una afinidad de union mayor en comparacion con los anticuerpos parentales.
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
EP2353611B1 (en) 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US20050271615A1 (en) 2002-08-30 2005-12-08 Doron Shabat Self-immolative dendrimers releasing many active moieties upon a single activating event
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
EP2100619B1 (en) 2003-02-20 2014-02-12 Seattle Genetics, Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of immune disorders
MXPA05014152A (es) * 2003-06-27 2006-05-25 Abgenix Inc Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
DK1725249T3 (en) * 2003-11-06 2014-03-17 Seattle Genetics Inc Monomethylvaline compounds capable of conjugating to ligands.
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1725586B1 (en) * 2004-03-02 2015-01-14 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
SI1912671T1 (en) 2005-07-18 2018-01-31 Seattle Genetics, Inc. Conjugates beta-glucuronide linker-drug
WO2007089149A2 (en) 2006-02-02 2007-08-09 Syntarga B.V. Water-soluble cc-1065 analogs and their conjugates
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
WO2009073445A2 (en) 2007-11-28 2009-06-11 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
WO2010064089A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Novel anti-cmet antibody
US20140112911A9 (en) 2008-12-02 2014-04-24 Liliane Goetsch Novel anti-cmet antibody
US20100152725A1 (en) 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
JP2012528240A (ja) 2009-05-28 2012-11-12 メルサナ セラピューティックス， インコーポレイテッド 可変速度放出リンカーを含むポリアル−薬物コンジュゲート
EP2287197A1 (en) 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
US9337942B2 (en) 2009-12-07 2016-05-10 Ntt Docomo, Inc. Propagation path estimation method and program and apparatus using the same
EP2545069A1 (en) 2010-03-10 2013-01-16 Novartis AG Streptococcus thermophilus bacterium
WO2011120053A1 (en) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
DE102010012915A1 (de) 2010-03-26 2011-09-29 Schaeffler Technologies Gmbh & Co. Kg Vorrichtung und Verfahren zur Ermittlung eines Schädigungszustands eines Radlagers
EP2402370A1 (en) 2010-06-29 2012-01-04 Pierre Fabre Médicament Novel antibody for the diagnosis and/or prognosis of cancer
WO2012153193A2 (en) * 2011-05-08 2012-11-15 Legochem Biosciences, Inc. Protein-active agent conjugates and method for preparing the same
CN103747804B (zh) 2011-06-10 2016-08-17 梅尔莎纳医疗公司 蛋白质-聚合物-药物共轭物
KR101463098B1 (ko) * 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
WO2013085925A1 (en) 2011-12-05 2013-06-13 Igenica, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
WO2013096901A1 (en) 2011-12-23 2013-06-27 Mersana Therapeutics, Inc. Pharmaceutical formulations for fumagillin derivative-phf conjugates
BR112014020697B1 (pt) * 2012-02-24 2024-01-09 Alteogen Inc Anticorpo modificado compreendendo um motivo contendo cisteína na terminação do anticorpo, conjugado anticorpo-droga modificado compreendendo uma droga ligada ao anticorpo modificado e método de produção do mesmo
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
US20140017265A1 (en) 2012-07-05 2014-01-16 Mersana Therapeutics, Inc. Terminally Modified Polymers and Conjugates Thereof
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
AU2013359506B2 (en) 2012-12-10 2018-05-24 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
KR20210118238A (ko) * 2013-03-15 2021-09-29 아비에 도이치란트 게엠베하 운트 콤파니 카게 항-egfr 항체 약물 접합체 제형
KR102150616B1 (ko) * 2013-09-12 2020-09-03 삼성전자주식회사 c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도
AU2015316522B2 (en) 2014-09-16 2021-01-21 Symphogen A/S Anti-met antibodies and compositions
WO2016165580A1 (zh) * 2015-04-17 2016-10-20 江苏恒瑞医药股份有限公司 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途
CN106188293A (zh) * 2015-04-17 2016-12-07 江苏恒瑞医药股份有限公司 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途
LT3626273T (lt) 2016-05-17 2021-03-10 Abbvie Biotherapeutics Inc. Anti-cmet antikūnų vaisto konjugatai ir jų naudojimo būdai

Also Published As

Publication number Publication date
IL294146A (en) 2022-08-01
PT3626273T (pt) 2021-03-09
IL304717A (en) 2023-09-01
JP2021107424A (ja) 2021-07-29
RU2018144315A3 (ru) 2020-07-22
PL3458102T3 (pl) 2020-12-14
US10383948B2 (en) 2019-08-20
KR20190008339A (ko) 2019-01-23
JP7150087B2 (ja) 2022-10-07
EP3458102B1 (en) 2020-06-17
ZA201808386B (en) 2022-07-27
CN109562189A (zh) 2019-04-02
CN109562189B (zh) 2021-12-31
KR20230028574A (ko) 2023-02-28
EP4233909A2 (en) 2023-08-30
US20170348429A1 (en) 2017-12-07
US20190314518A1 (en) 2019-10-17
KR20220137158A (ko) 2022-10-11
HRP20201186T1 (hr) 2020-11-13
SG10201914095SA (en) 2020-03-30
IL262869A (en) 2018-12-31
BR112018073574A2 (pt) 2019-03-19
PL3626273T3 (pl) 2021-06-14
IL294146B1 (en) 2023-09-01
US20230321271A1 (en) 2023-10-12
MX2018014175A (es) 2020-02-07
US20200215200A1 (en) 2020-07-09
RS60663B1 (sr) 2020-09-30
KR102512597B1 (ko) 2023-03-23
EP3626273A1 (en) 2020-03-25
JP6870161B1 (ja) 2021-05-12
JP2022185003A (ja) 2022-12-13
DK3458102T3 (da) 2020-07-27
HUE050398T2 (hu) 2020-12-28
LT3626273T (lt) 2021-03-10
EP3458102A1 (en) 2019-03-27
RU2740996C2 (ru) 2021-01-22
US10603389B2 (en) 2020-03-31
NZ748314A (en) 2023-07-28
RS61659B1 (sr) 2021-04-29
WO2017201204A1 (en) 2017-11-23
AU2017268342B2 (en) 2023-08-17
AU2017268342A1 (en) 2018-11-29
CN114177308B (zh) 2024-07-09
CN114246953B (zh) 2024-07-09
IL294146B2 (en) 2024-01-01
IL262869B (en) 2022-07-01
CA3024386C (en) 2024-01-02
ES2864150T3 (es) 2021-10-13
CN114246953A (zh) 2022-03-29
SMT202000467T1 (it) 2020-11-10
EP4233909A3 (en) 2023-09-20
DK3626273T3 (da) 2021-02-08
KR102449294B1 (ko) 2022-09-30
CY1123858T1 (el) 2022-05-27
SI3626273T1 (sl) 2021-04-30
HUE053332T2 (hu) 2021-06-28
EP3804765A1 (en) 2021-04-14
SG11201810034XA (en) 2018-12-28
JP2019521087A (ja) 2019-07-25
SMT202100122T1 (it) 2021-05-07
JP2021073247A (ja) 2021-05-13
PT3458102T (pt) 2020-08-17
LT3458102T (lt) 2020-08-25
EP3626273B1 (en) 2020-12-30
CY1123256T1 (el) 2021-10-29
HRP20210326T1 (hr) 2021-04-02
ES2811351T3 (es) 2021-03-11
CN114177308A (zh) 2022-03-15
US20180250418A1 (en) 2018-09-06
SI3458102T1 (sl) 2020-09-30
CA3024386A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
RU2018144315A (ru) КОНЪЮГАТЫ АНТИТЕЛА К cMet И ЛЕКАРСТВЕННОГО СРЕДСТВА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2020130125A1 (ja) 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
JP7608164B2 (ja) 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ
JP7458981B2 (ja) 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ
EP3042669B1 (en) Antitumor agent and antitumor effect enhancer
RU2492860C2 (ru) Антиопластические комбинации, содержащие нкi-272 и винорелбин
Mer et al. Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies
KR20210150470A (ko) A-노르-5α안드로스테인 화합물계 약물 및 항암제의 병용
WO2024193570A9 (en) Combination of antibody-drug conjugate and cancer therapy, and use thereof
JP2025513620A (ja) 抗体－薬物コンジュゲートとｅｚｈ１阻害剤および／またはｅｚｈ２阻害剤との組合せ
WO2025064733A1 (en) Improved linker-payloads for antibody conjugation, pharmaceutical compositions and applications thereof
HK40043732A (en) Combination of antibody-drug conjugate and tubulin inhibitor
CN118662651A (zh) 含抗her3抗体药物偶联物的组合物和用途
HK40064358A (en) Combination of antibody-drug conjugate with parp inhibitor
HK40054690A (en) Combination of antibody-drug conjugate and kinase inhibitor